elosulfase alfa

Ukraine

Drugs containing this active substance

VIMIZIM

The drug is indicated for the treatment of mucopolysaccharidosis type IVA (Morquio A syndrome) in patients of any age.

Form: concentrate for infusion solution

Active substance	Dosage
elosulfase alfa	1 mg/ml

Manufacturer: Wetter Pharma-Fertigung GmbH & Co. KG (manufacturing bulk products, primary packaging, sterility testing, dot-blot and bioburden testing during production, visual inspection, storage)